FDG-PET Accurately Tracks Tx Response in Metastatic Breast CancerFDG-PET Accurately Tracks Tx Response in Metastatic Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium, Jennifer Specht, MD, of the University of Washington and Fred Hutch Cancer Center, Seattle, presented results from the ECOG-ACRIN FEATURE trial, a phase II study evaluating fluorodeoxyglucose…
Breast cancer drug boosts leukemia treatment: Unexpected duo shows promise in overcoming resistanceBreast cancer drug boosts leukemia treatment: Unexpected duo shows promise in overcoming resistance
A research team at Oregon Health & Science University has discovered a promising new drug combination that may help people with acute myeloid leukemia overcome resistance to one of the most common frontline therapies.
Novo Nordisk Cuts Wegovy Prices in China Ahead of Generic ThreatNovo Nordisk Cuts Wegovy Prices in China Ahead of Generic Threat
Post Content Post Content
Misinformation Regarding Progression or Recurrence in Patients With Breast CancerMisinformation Regarding Progression or Recurrence in Patients With Breast Cancer
This survey study of US adults with a history of breast cancer reports the prevalence of misinformation and its association with recurrence fears and treatment adherence.
Study finds a better way to screen for breast cancerStudy finds a better way to screen for breast cancer
A pioneering study has found that an individualized approach to breast cancer screening that assesses patients’ risk, rather than annual mammograms, can lower the chance of more advanced cancers, while still safely match people to the amount of screening they need.
GLP-1s and Obesity Cancers; Cannabis’ New Legal Status; Celebrity Cancer DiagnosesGLP-1s and Obesity Cancers; Cannabis’ New Legal Status; Celebrity Cancer Diagnoses
(MedPage Today) — GLP-1 agonists may have little impact on risk of obesity-related cancers, according to a systematic review and meta-analysis of randomized studies. (Annals of Internal Medicine) The FDA granted accelerated approval for the subcutaneous… (MedPage Today) — GLP-1 agonists may have little impact on risk of obesity-related cancers, according to a systematic Read More
Anastrozole, Letrozole, and Exemestane in Postmenopausal Breast CancerAnastrozole, Letrozole, and Exemestane in Postmenopausal Breast Cancer
This comparative effectiveness research compares disease-free survival and overall survival 5 and 8 years after the initiation of endocrine therapy in postmenopausal women with hormone receptor–positive early-stage breast cancer.
Differential Effectiveness of Aromatase Inhibitors in HR-Positive Breast CancerDifferential Effectiveness of Aromatase Inhibitors in HR-Positive Breast Cancer
Oncology
Rb1 identified as predictive biomarker for new therapeutic strategy in some breast cancersRb1 identified as predictive biomarker for new therapeutic strategy in some breast cancers
A new study published in Science Translational Medicine by researchers at The University of Texas MD Anderson Cancer Center details a therapeutic vulnerability in patients with an aggressive subtype of triple-negative breast cancer.
Incretin Therapies After Bariatric Surgery Linked to Lower Risk of Alcohol DisorderIncretin Therapies After Bariatric Surgery Linked to Lower Risk of Alcohol Disorder
(MedPage Today) — Treatment with incretin-based weight-loss medications, like GLP-1 receptor agonists, after bariatric surgery was associated with significantly lower risks of alcohol use disorder (AUD) and initiation of medications for AUD compared…